Company: BIAF
Filing Date: 2025-10-15
Form Type: 8-K
Source: 0001493152-25-018093
Chunk: 0

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-15
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

On
October 14, 2025, bioAffinity Technologies, Inc., a Delaware corporation (the “ Company”), received a letter from The Nasdaq
Stock Market, LLC (“ Nasdaq”) stating that the Nasdaq Hearings Panel has found the Company to be in compliance with Listing
Rule 5550(a)(2) (the “ Minimum Bid Price Rule”) and 5550(b)(1) (the “ Minimum Stockholders’ Equity Rule”).
The letter also indicated that the Company will be subject to a mandatory panel monitor for a period of one year. If, within that one-year
monitoring period, the Company fails to comply with the Minimum Stockholders’ Equity Rule, the Company will not be permitted additional
time to regain compliance. However, the Company will have an opportunity to request a new hearing with the Nasdaq Hearings Panel prior
to the Company’s securities being delisted from Nasdaq.

On
October 15, 2025, the Company issued a press release announcing that it has regained compliance with Nasdaq listing requirements.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.